Novartis Continue To Battle Roche To Create The Number One Lung Cancer Drug

Novartis Vs Roche

The Disease Diagnosis Innovation is becoming a battle to produce the leading drug for lung cancer is heating up.On one side is Zykadia from Novartis. On the other is a product called Alecensa from Roche, their current rival. Both healthcare companies already have the approval they need to be used as a second-line treatment option when Xalkori is not an option. Now the battle is on to become the number one option.…

Continue Reading